HOUSTON, Oct. 4, 2024
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)
("Moleculin" or the "Company"), a late stage pharmaceutical company
with a broad portfolio of drug candidates targeting hard-to-treat
tumors and viruses, today announced its participation at two
upcoming investor conferences.
Details of the upcoming presentations are as follows:
3rd Annual ROTH Healthcare Opportunities
Conference
- Format: Panel - Innovative Therapies for Liquid Tumors
- The panel will cover the drugs in development by the presenting
companies and where they fit competitively for the initial
indication as well as for potential subsequent indications, and
upcoming data readouts.
- Date: Wednesday, October 9,
2024
- Time: 1:15 – 1:55 PM ET
Panel presentations will be accessible by those registered to
attend the conference. In addition to the panel presentation,
management will be available to participate in in-person one-on-one
meetings with qualified members of the investor community who are
registered to attend the event.
2024 Healthcare Virtual Summit, Presented by Maxim Group and
hosted by M-Vest
- Format: Fireside chat
- Date: Wednesday, October 16,
2024
- Time: 3:00 PM ET
This conference will be live on M-Vest. To attend, just sign up
to become an M-Vest member. Click Here to Reserve Your Seat.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage
pharmaceutical company advancing a pipeline of therapeutic
candidates addressing hard-to-treat tumors and viruses. The
Company's lead program, Annamycin, is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms and
to eliminate the cardiotoxicity common with currently prescribed
anthracyclines. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin
R/R AML AnnAraC Clinical Evaluation)
Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating
Annamycin in combination with cytarabine, together referred to as
AnnAraC, for the treatment of relapsed or refractory acute myeloid
leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the
Company believes it has substantially de-risked the development
pathway towards a potential approval for Annamycin for the
treatment of AML. This study is subject to appropriate future
filings with potential additional feedback from the FDA and their
foreign equivalents.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers. Moleculin is also engaged in the development of a
portfolio of antimetabolites, including WP1122 for the potential
treatment of pathogenic viruses, as well as certain cancer
indications.
For more information about the Company, please visit
www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-two-upcoming-investor-conferences-302267367.html
SOURCE Moleculin Biotech, Inc.